What the work claims
That a substance secreted by Penicillium rubens selectively kills certain bacteria without harming human cells, that this effect is concentration- and duration-dependent, and that misuse invites resistance.
How it was done
Fleming observed a Penicillium rubens contaminant on an agar plate and noted lysis of adjacent Staphylococcus aureus colonies; he isolated the active substance from mould broth, tested it against bacterial cultures, and named it ‘penicillin’ on 7 March 1929.
What holds up
The observation of zone-of-inhibition lysis around P. rubens is directly verified. Penicillin’s selective activity against Gram-positive bacteria (including staphylococci) and Neisseria gonorrhoeae — but not Salmonella typhi or Paratyphi — is confirmed. Fleming’s early warning about subtherapeutic dosing and short duration inducing resistance is documented and prescient.
What does not
Fleming did not purify penicillin to clinical grade. He did not treat human patients with it. He did not establish pharmacokinetics, dosing regimens, or scalable production. His work did not demonstrate efficacy in vivo, nor did it overcome instability or toxicity barriers.
Why it matters beyond the lab
It established the conceptual scaffold for antibiotic discovery: contamination as clue, selective toxicity as goal, and resistance as inevitable consequence of incomplete suppression. Every subsequent antibiotic programme inherits this logic — not its success, but its constraints.
Is it worth your time
Yes — it is the first documented observation of targeted antibacterial activity by a fungal metabolite, and the first identification of conditions that induce resistance. It is foundational to antibiotic science, not because it cured disease, but because it revealed a principle: selective microbial inhibition and its fragility.
